Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on the day's biggest business stories
Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Sign up for Axios NW Arkansas
Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters
GSK's Twinrix vaccine. Photo: Sven Hoppe/picture alliance via Getty Images
Global stay-at-home orders stemming from the coronavirus pandemic — especially those in the U.S. — have led to steep sales declines in routine vaccinations.
The big picture: Although more people are getting their vaccines now, "there remains some way to go to get back to pre-COVID levels for adult vaccinations," GlaxoSmithKline CEO Emma Walmsley said on an investor call Wednesday.
By the numbers:
- Sales of GlaxoSmithKline's vaccines in the second quarter plummeted 29% from the same period in 2019, totaling £1.13 billion.
- Pfizer's vaccine sales fell 9% to $1.25 billion. The drop was especially severe in the U.S. for Pfizer's main vaccine, Prevnar 13, due to the "unfavorable impact of disruptions to wellness visits," the company said.
- Sanofi said its vaccine sales slumped 7% to €927 million because of the "global confinements."
- Merck will report its second-quarter results on Friday. Wall Street expects Merck's vaccine sales dropped 26% year over year.
Yes, but: The major vaccine manufacturers said uptake was rising a lot in Europe and developing countries.
- But global sales dragged because of the shutdowns in the U.S., where drug companies charge the highest prices in the world.
Go deeper: The pandemic has put a lot of children behind the curve on routine vaccinations